Venetoclax (Venclyxto) 10/50/100mg Tablets | EU-Approved BCL-2 Inhibitor for CLL/SLL & AML | GLT

Generic Information: Venclyxto (Venetoclax)

Venclyxto (venetoclax) is the world's first-in-class, orally bioavailable, selective inhibitor of the B-cell lymphoma-2 (BCL-2) protein, developed by AbbVie and marketed in Europe as Venclyxto. It was granted approval by the European Medicines Agency (EMA) in 2016 for chronic lymphocytic leukemia, and is now approved across major markets worldwide for CLL/SLL and AML indications. The product supplied by GLT is the EU-marketed originator version, sourced through licensed channels with full documentation.

What Is Venclyxto (Venetoclax) Used For?

Venclyxto (venetoclax) is indicated for the treatment of adult patients with:

• Chronic lymphocytic leukemia (CLL) — previously untreated (with obinutuzumab) or relapsed/refractory disease, including 17p deletion or TP53-mutated CLL.
• Small lymphocytic lymphoma (SLL).
• Acute myeloid leukemia (AML) — in combination with azacitidine or low-dose cytarabine for newly diagnosed AML in adults ineligible for intensive induction chemotherapy.

In pivotal trials, venetoclax-based fixed-duration therapy delivered superior progression-free survival and high rates of undetectable minimal residual disease (MRD) in CLL (CLL14, MURANO), and in AML (VIALE-A) venetoclax plus azacitidine achieved a complete response rate of 66.4% with median overall survival of 14.7 months in unfit patients.

How Does Venclyxto (Venetoclax) Work?

Venetoclax selectively binds the anti-apoptotic BCL-2 protein, which is over-expressed in CLL cells and AML blasts and protects them from programmed cell death. By displacing pro-apoptotic proteins such as BIM from BCL-2, venetoclax re-activates the apoptotic pathway, and the malignant cell self-destructs. This targeted mechanism produces deep remissions with a manageable, outpatient-usable safety profile.

Indications

• Chronic lymphocytic leukemia (CLL) — first-line (combination) and relapsed/refractory
• Small lymphocytic lymphoma (SLL)
• Acute myeloid leukemia (AML) — combination therapy in unfit patients
• Active in high-risk 17p deletion / TP53-mutated disease

Dosage & Administration

Available strengths: 10mg × 14's; 50mg × 7's; 100mg × 112's.

For CLL, treatment follows a 5-week once-daily ramp-up (20 mg → 50 mg → 100 mg → 200 mg → 400 mg) with mandatory tumor lysis syndrome (TLS) prophylaxis and monitoring, then continues at 400 mg once daily in fixed-duration combination regimens. For AML with azacitidine, ramp up 100 mg → 200 mg → 400 mg over cycle 1 days 1–3, then 400 mg daily. Tablets are taken orally with food and water, swallowed whole, at the same time each day. Treatment must be initiated and supervised by an experienced hematologist/oncologist.

Side Effects

The most clinically important risk is tumor lysis syndrome (TLS) during initiation in high-tumour-burden patients. Common adverse reactions include neutropenia (with infection risk), diarrhoea, nausea, anaemia, thrombocytopenia, fatigue and cough. Strong CYP3A4 inhibitors/inducers require dose adjustment or avoidance. Venetoclax can cause fetal harm; effective contraception is required during and after treatment.

Storage

Store Venclyxto tablets at controlled room temperature (20–25 °C) in the original packaging, protected from moisture. Keep out of reach of children. Ambient (non-cold-chain) shipping is suitable for oral tablets.

Why Choose the GLT?

• EU originator version — EMA-approved Venclyxto (venetoclax) sourced through licensed channels.
• First-in-class BCL-2 inhibition — deep, durable remissions in CLL/SLL and AML as fixed-duration oral therapy.
• Full documentation — every batch ships with CoA, CPP and batch traceability.
• Multi-country sourcing expertise — GLT (GIVE LIFE TIME LIMITED) is a Hong Kong–licensed pharmaceutical supplier serving institutions and patients worldwide.

How to Order Venclyxto (Venetoclax) from GLT?

1. Contact us via WhatsApp +86 15234153837 or email [email protected] with the product name, specification and quantity.
2. Receive a formal quotation, payment instructions and estimated delivery time.
3. Complete payment via our secure payment channel (Hao Yi Lian / 好易联).
4. Goods are dispatched with batch documentation; tracking provided until delivery.

We serve both licensed institutions (hospital procurement, pharmacies, importers) and individual patients. A valid prescription may be requested before dispatch.

FAQ

1. What strengths of Venclyxto (venetoclax) are available?

Venclyxto is available as 10mg × 14's; 50mg × 7's; 100mg × 112's film-coated tablets. CLL therapy uses a 5-week ramp-up to the 400 mg daily target dose.

2. What is the difference between Venclexta and Venclyxto?

They are the same molecule (venetoclax) from the same developer (AbbVie): Venclexta is the trade name used in the US and China, while Venclyxto is the trade name used in Europe.

3. Why is the ramp-up schedule so important?

The gradual 5-week dose ramp-up, hydration and lab monitoring keep tumor lysis syndrome (TLS) risk manageable during initiation and are mandatory safety measures.

4. How is Venclyxto shipped internationally?

As an oral tablet, Venclyxto ships via ambient temperature-controlled courier with full batch documentation. Typical delivery is 7–14 days depending on destination.

5. Can I order Venclyxto for personal use?

GLT serves both institutions and individual patients. Individual buyers should hold a valid prescription and use this medicine under hematologist/oncologist supervision.